BCL2 and cancer: Senolytics focus on targeting anti-apoptotic pathways that are overexpressed in cancer cells, such as the BCL-2 family and FOXO4-p53 interaction, with agents like HDAC inhibitors (panobinostat), BCL-2 inhibitors (ABT-737, ABT-263), and natural compounds (quercetin, navitoclax, fisetin).